Molecular Imaging

Catch up on the top radiology content of the past week.

In addition to detecting more than double the number of distant lymph nodes and distant lesions in comparison to conventional imaging with computed tomography (CT), PSMA PET/CT reportedly changed management for 32 percent of patients.

The FDA has accepted Lantheus' abbreviated new drug application for a generic Lutathera, just months after Novartis announced positive phase 3 data supporting a first-line indication for the radiopharmaceutical in neuroendocrine tumors.

In a recent proof-of-concept trial assessing the combination of aducanumab infusion with MRI-guided focused ultrasound to open the blood-brain barrier, researchers found significant reductions in amyloid-beta load at 26 weeks in patients with Alzheimer’s disease.

Catch up on the top radiology content of the past week.

Catch up on the top radiology content of the past week.

Catch up on the top radiology content of the past week.

The Biograph Vision.X positron emission tomography/computed tomography (PET/CT) reportedly offers an industry-leading time of flight (TOF) and detector technology that facilitates the diagnosis of smaller lesions.

Catch up on the top radiology content of the past week.

For patients who had a complete metabolic response to radiation treatment for head and neck cancer, the authors of a recent study found that surveillance imaging with PET/CT, MRI or CT did not improve outcomes in comparison to expectant management.

In a recent video interview series, Dushyant Sahani, M.D., discussed the critical role of contrast media in diagnostic imaging, lessons learned from the contrast media shortage, key considerations with generic agents and currently unmet needs with contrast agents.

Imaging experts discuss the challenges with traditional imaging modalities for prostate cancer, commenting on the bone scan and CT scan.

Experts review traditional imaging modalities for prostate cancer, highlighting the most commonly used modalities.

Catch up on the top radiology content of the past week.

Various organizations have applauded the decision by the CMS to remove National Coverage Determination (NCD) limitations to coverage for amyloid PET scans, including the limitation of Medicare or Medicaid coverage to one PET scan per a patient’s lifetime. It remains to be seen, however, how coverage decisions will be made by local Medicare Administrative Contractors (MACs).

Catch up on the top radiology content of the past week.

In a study of over 25,000 Medicare beneficiaries with mild cognitive decline or dementia, researchers found that obtaining amyloid positron emission tomography (PET) scans resulted in no statistically significant differences upon subsequent hospitalization and emergency department visit rates at one year.

Catch up on the top radiology news of the past week.

iMPI technology represents a significant advancement in the field of medical imaging that may potentially revolutionize the way endovascular interventions are conducted.

Catch up on the top radiology news of the past week.

For cT1 renal masses < 4 cm and renal masses < 2 cm, the PET/CT agent 89Zr-DFO-girentuximab had respective sensitivity rates of approximately 85 percent and 96.7 percent for diagnosing clear cell renal cell carcinoma, according to research recently presented at the European Association of Nuclear Medicine (EANM) 2023 Congress.

Catch up on the top radiology content of the past week.

In a recent interview, Sophia Rose O’Brien, M.D., shared her insights on the roles and limitations of FDG PET/CT and FES PET/CT in the imaging of patients with metastatic breast cancer.

Catch up on the top five most viewed content at Diagnostic Imaging in August 2023.

Catch up on the top radiology content of the past week.

In a recent study examining neuroimaging biomarkers of Alzheimer’s disease, researchers found that neocortical tau pathology exhibited the strongest association with cognitive decline and the use of tau positron emission tomography (tau-PET) provided the best prognostic value of all neuroimaging modalities in this patient population.

Through a new technology add-on payment (NTAP), the use of Cytalux will reportedly be reimbursed by CMS up to 65 percent of the cost of the molecular imaging agent, which is FDA-approved for intraoperative imaging of ovarian and lung cancer.

Catch up on the top radiology content of the past week.

Catch up on the most viewed content at Diagnostic imaging in July 2023.

Catch up on the top radiology news of the past week.